{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T08:51:47Z","timestamp":1780044707868,"version":"3.53.1"},"reference-count":61,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2021,1,25]],"date-time":"2021-01-25T00:00:00Z","timestamp":1611532800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["dom-pubs.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Diabetes Obesity Metabolism"],"published-print":{"date-parts":[[2021,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aim<\/jats:title>\n                    <jats:p>To undertake a cost\u2010effectiveness analysis of dapagliflozin in treating high\u2010risk patients with type 2 diabetes mellitus (T2DM), using both directly observed events in the DECLARE\u2010TIMI 58 trial and surrogate risk factors to predict endpoints not captured within the trial.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>An established T2DM model was adapted to integrate survival curves derived from the DECLARE\u2010TIMI 58 trial, and extrapolated over a lifetime for all\u2010cause mortality, hospitalization for heart failure, stroke, myocardial infarction, hospitalization for unstable angina, and end\u2010stage kidney disease. The economic analysis considered the overall DECLARE trial population, as well as reported patient subgroups. Total and incremental costs, life\u2010years and quality\u2010adjusted life\u2010years associated with dapagliflozin versus placebo were estimated from the perspective of the UK healthcare payer.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>In the UK setting, treatment with dapagliflozin compared to placebo was estimated to be dominant, with an expected increase in quality\u2010adjusted life\u2010years from 10.43 to 10.48 (+0.06) and a reduction in lifetime total costs from \u00a339\u2009451 to \u00a336\u2009899 (\u2212\u00a32552). Across all patient subgroups, dapagliflozin was estimated to be dominant, with the greatest absolute benefit in the prior heart failure subgroup (incremental lifetime costs \u2212\u00a34150 and quality\u2010adjusted life\u2010years +0.11).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The results of this study demonstrate that dapagliflozin compared to placebo appears to be cost\u2010effective, when considering evidence reported from the DECLARE\u2010TIMI 58 trial, at established UK willingness\u2010to\u2010pay thresholds. The findings highlight the potential of dapagliflozin to have a meaningful impact in reducing the economic burden of T2DM and its associated complications across a broad T2DM population.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/dom.14308","type":"journal-article","created":{"date-parts":[[2020,12,28]],"date-time":"2020-12-28T12:14:39Z","timestamp":1609157679000},"page":"1020-1029","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":29,"title":["The cost\u2010effectiveness of dapagliflozin in treating high\u2010risk patients with type 2 diabetes mellitus: An economic evaluation using data from the DECLARE\u2010TIMI 58 trial"],"prefix":"10.1111","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7488-9058","authenticated-orcid":false,"given":"Phil","family":"McEwan","sequence":"first","affiliation":[{"name":"Health Economics and Outcomes Research Ltd  Cardiff UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angharad R.","family":"Morgan","sequence":"additional","affiliation":[{"name":"Health Economics and Outcomes Research Ltd  Cardiff UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Boyce","sequence":"additional","affiliation":[{"name":"Health Economics and Outcomes Research Ltd  Cardiff UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Klas","family":"Bergenheim","sequence":"additional","affiliation":[{"name":"BioPharmaceuticals R&amp;D AstraZeneca  Gothenburg Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ingrid A.M.","family":"Gause\u2010Nilsson","sequence":"additional","affiliation":[{"name":"BioPharmaceuticals R&amp;D AstraZeneca  Gothenburg Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deepak L.","family":"Bhatt","sequence":"additional","affiliation":[{"name":"TIMI Study Group, Division of Cardiovascular Medicine Brigham and Women's Hospital and Harvard Medical School  Boston Massachusetts USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1040-6229","authenticated-orcid":false,"given":"Lawrence A.","family":"Leiter","sequence":"additional","affiliation":[{"name":"Li Ka Shing Knowledge Institute, St Michael's Hospital University of Toronto  Toronto Ontario Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter A.","family":"Johansson","sequence":"additional","affiliation":[{"name":"BioPharmaceuticals R&amp;D AstraZeneca  Gothenburg Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5702-7584","authenticated-orcid":false,"given":"Ofri","family":"Mosenzon","sequence":"additional","affiliation":[{"name":"Hadassah Medical Center, Faculty of Medicine Hebrew University of Jerusalem  Jerusalem Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7830-9994","authenticated-orcid":false,"given":"Avivit","family":"Cahn","sequence":"additional","affiliation":[{"name":"Hadassah Medical Center, Faculty of Medicine Hebrew University of Jerusalem  Jerusalem Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2839-8404","authenticated-orcid":false,"given":"John P.H.","family":"Wilding","sequence":"additional","affiliation":[{"name":"University of Liverpool  Liverpool UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2021,1,25]]},"reference":[{"key":"e_1_2_9_2_1","unstructured":"International Diabetes Federation.IDF Diabetes Atlas \u2010 8th Edition.2017.https:\/\/diabetesatlas.org\/resources\/2017-atlas.html"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.2337\/diaclin.26.2.77"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/dme.13062"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.hjr.0000368191.86614.5a"},{"key":"e_1_2_9_6_1","unstructured":"National Institute for Health and Care Excellence.Clinical guideline [NG28]: type 2 diabetes in adults: management.2017.https:\/\/www.nice.org.uk\/guidance\/ng28. (Accessed 25 August 2020)."},{"key":"e_1_2_9_7_1","unstructured":"Scottish Intercollegiate Guideline Network.SIGN 154: pharmacological management of glycaemic control in people with type 2 diabetes.2017."},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.2337\/dci18-0033"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehz486"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.117.029190"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1177\/1479164115616901"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2011-2260"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehx511"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.117.032031"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1504720"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1611925"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1812389"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1911303"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(18)30141-4"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1515920"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1811744"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfz290"},{"key":"e_1_2_9_23_1","unstructured":"AJMC.Dapagliflozin Meets All Targets in Patients with Chronic Kidney Disease With and Without Diabetes.2020.https:\/\/www.ajmc.com\/view\/dapagliflozin-meets-all-targets-in-patients-with-chronic-kidney-disease-with-and-without-diabetes"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(17)30258-9"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.13627"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.13077"},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.119.039996"},{"key":"e_1_2_9_28_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.119.040130"},{"issue":"7","key":"e_1_2_9_29_1","first-page":"A350","article-title":"The cost\u2010effectiveness of Dapagliflozin in combination with insulin for the treatment of type 2 diabetes mellitus (T2dm) in Spain","volume":"17","author":"S\u00e1nchez\u2010Covisa J","year":"2014","journal-title":"Value Health"},{"key":"e_1_2_9_30_1","doi-asserted-by":"publisher","DOI":"10.1080\/13696998.2018.1434182"},{"issue":"7","key":"e_1_2_9_31_1","first-page":"A343","article-title":"Dapagliflozin (Forxiga\u00ae) versus Glipizide as add\u2010on therapies in type 2 diabetes mellitus (T2dm); an update of the cost\u2010effectiveness based on long\u2010term clinical evidence from UKNhs perspective","volume":"17","author":"Charokopou M","year":"2014","journal-title":"Value Health"},{"key":"e_1_2_9_32_1","doi-asserted-by":"publisher","DOI":"10.1111\/dme.12772"},{"key":"e_1_2_9_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pcd.2014.04.007"},{"key":"e_1_2_9_34_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40261-016-0410-2"},{"key":"e_1_2_9_35_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12913-015-1139-y"},{"issue":"7","key":"e_1_2_9_36_1","first-page":"A347","article-title":"Cost\u2010effectiveness of Dapagliflozin compared to Dpp\u20104 inhibitors as triple therapy in combination with metformin and a Sulphonylurea in the treatment of type 2 diabetes mellitus from a UK health care perspective","volume":"17","author":"Charokopou M","year":"2014","journal-title":"Value Health"},{"key":"e_1_2_9_37_1","doi-asserted-by":"publisher","DOI":"10.1080\/03007995.2016.1257978"},{"key":"e_1_2_9_38_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0165629"},{"issue":"7","key":"e_1_2_9_39_1","first-page":"A347","article-title":"Cost\u2010effectiveness of dapagliflozin versus Dpp\u20104 inhibitors as monotherapy in the treatment of type 2 diabetes mellitus from a UK health care perspective","volume":"17","author":"Charokopou M","year":"2014","journal-title":"Value Health"},{"key":"e_1_2_9_40_1","doi-asserted-by":"publisher","DOI":"10.1080\/14656566.2018.1543408"},{"key":"e_1_2_9_41_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-004-1527-z"},{"key":"e_1_2_9_42_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-013-2940-y"},{"key":"e_1_2_9_43_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(98)07019-6"},{"key":"e_1_2_9_44_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pcd.2014.04.007"},{"key":"e_1_2_9_45_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40261-013-0155-0"},{"key":"e_1_2_9_46_1","doi-asserted-by":"publisher","DOI":"10.1186\/2191-1991-3-11"},{"issue":"1","key":"e_1_2_9_47_1","first-page":"20","article-title":"US cost\u2010effectiveness of saxagliptin in type 2 diabetes mellitus","volume":"4","author":"Bergenheim K","year":"2012","journal-title":"Am J Pharm Benefits"},{"key":"e_1_2_9_48_1","doi-asserted-by":"publisher","DOI":"10.1089\/dia.2011.0092"},{"key":"e_1_2_9_49_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pcd.2011.09.003"},{"key":"e_1_2_9_50_1","doi-asserted-by":"publisher","DOI":"10.2165\/11597060-000000000-00000"},{"key":"e_1_2_9_51_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.14162"},{"key":"e_1_2_9_52_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12962-015-0038-8"},{"key":"e_1_2_9_53_1","unstructured":"Office for National Statistics.National life tables: UK.2019.https:\/\/www.ons.gov.uk\/peoplepopulationandcommunity\/birthsdeathsandmarriages\/lifeexpectancies\/datasets\/nationallifetablesunitedkingdomreferencetables"},{"key":"e_1_2_9_54_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.13217"},{"key":"e_1_2_9_55_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(19)30180-9"},{"key":"e_1_2_9_56_1","unstructured":"Haymarket Media Group Ltd. Monthly Index of Medical Specialities.https:\/\/www.mims.co.uk\/"},{"key":"e_1_2_9_57_1","unstructured":"National Institute for Health and Care Excellence (NICE).Guide to the methods of technology appraisal.2013.https:\/\/www.nice.org.uk\/process\/pmg9\/resources\/guide\u2010to\u2010the\u2010methods\u2010of\u2010technology\u2010appraisal\u20102013\u2010pdf\u20102007975843781. (Accessed 25 August 2020)."},{"key":"e_1_2_9_58_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrendo.2017.151"},{"key":"e_1_2_9_59_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.13612"},{"issue":"8","key":"e_1_2_9_60_1","first-page":"S138","article-title":"Eligibility varies among the 4 sodium\u2010glucose cotransporter\u20102 inhibitor cardiovascular outcomes trials: implications for the general type 2 diabetes US population","volume":"24","author":"Wittbrodt ET","year":"2018","journal-title":"Am J Manag Care"},{"key":"e_1_2_9_61_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40261-018-0620-x"},{"key":"e_1_2_9_62_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdiacomp.2017.10.006"}],"container-title":["Diabetes, Obesity and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/dom.14308","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/dom.14308","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/dom-pubs.pericles-prod.literatumonline.com\/doi\/pdf\/10.1111\/dom.14308","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T05:24:29Z","timestamp":1761888269000},"score":1,"resource":{"primary":{"URL":"https:\/\/dom-pubs.pericles-prod.literatumonline.com\/doi\/10.1111\/dom.14308"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,25]]},"references-count":61,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,4]]}},"alternative-id":["10.1111\/dom.14308"],"URL":"https:\/\/doi.org\/10.1111\/dom.14308","archive":["Portico"],"relation":{},"ISSN":["1462-8902","1463-1326"],"issn-type":[{"value":"1462-8902","type":"print"},{"value":"1463-1326","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,25]]},"assertion":[{"value":"2020-10-02","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-12-20","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-01-25","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}